I Glenn Cohen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2501538/publications.pdf

Version: 2024-02-01

290 papers

4,085 citations

30 h-index 55 g-index

322 all docs $\begin{array}{c} 322 \\ \text{docs citations} \end{array}$

times ranked

322

4234 citing authors

#	Article	IF	CITATIONS
1	CRISPR immunity: a case study for justified somatic genetic modification?. Journal of Medical Ethics, 2022, 48, 83-85.	1.8	2
2	When Failure Is Not an Option: The Independent Panel Pandemic Report. American Journal of Medicine, 2022, 135, 131-132.	1.5	1
3	The Pandemic Preparedness Program. JAMA - Journal of the American Medical Association, 2022, , .	7.4	6
4	Supreme Court Ruling on the Texas Abortion Law. JAMA - Journal of the American Medical Association, 2022, 327, 621.	7.4	8
5	Transparency and the Doctor–Patient Relationship — Rethinking Conflict-of-Interest Disclosures. New England Journal of Medicine, 2022, 386, 300-302.	27.0	1
6	At-home Diagnostics and Diagnostic Excellence. JAMA - Journal of the American Medical Association, 2022, 327, 523.	7.4	5
7	Al reflections in 2021. Nature Machine Intelligence, 2022, 4, 5-10.	16.0	0
8	How NFTs could transform health information exchange. Science, 2022, 375, 500-502.	12.6	32
9	Sharing Clinical Notes. JAMA - Journal of the American Medical Association, 2022, 327, 717.	7.4	9
10	The next two decades of mifepristone at FDA: History as destiny,. Contraception, 2022, 109, 1-7.	1.5	4
11	Mitigating Racial Bias in Machine Learning. Journal of Law, Medicine and Ethics, 2022, 50, 92-100.	0.9	31
12	Deadly Legacy—The 510(k) Path to Medical Device Clearance. JAMA Surgery, 2022, 157, 185.	4.3	4
13	Who will oversee the ethical limits of human embryo research?. Nature Biotechnology, 2022, 40, 463-464.	17.5	4
14	Emerging Ethical Considerations for the Use of Artificial Intelligence inÂOphthalmology. Ophthalmology Science, 2022, 2, 100141.	2.5	7
15	"l'd feel like someone was watchin' me… watching for a good reason― perceptions of data privacy, access, and sharing in the context of real-time PrEP adherence monitoring among HIV-negative MSM with substance use. AIDS and Behavior, 2022, 26, 2981-2993.	2.7	4
16	Al, Explainability, and Safeguarding Patient Safety in Europe., 2022,, 91-102.		12
17	Strengthening the Power of Health Care Insurers to Regulate Medical Device Risks. , 2022, , 268-280.		0
18	Regulating Posttrial Access to In-Dwelling Class III Neural Devices. , 2022, , 256-267.		1

#	Article	IF	CITATIONS
19	The mHealth Power Paradox. , 2022, , 63-76.		14
20	Ensuring Patient Safety and Benefit in Use of Medical Devices Granted Expedited Approval. , 2022, , 217-228.		11
21	Product Liability Suits for FDA-Regulated AI/ML Software. , 2022, , 22-35.		2
22	Digital Home Health During the COVID-19 Pandemic. , 2022, , 141-160.		0
23	IP and FDA Regulation of De Novo Medical Devices. , 2022, , 117-128.		0
24	<scp>A "DESIâ€</scp> for Devices <scp>?</scp> ., 2022, , 129-140.		0
25	Cybersecurity of Medical Devices. , 2022, , 51-62.		1
26	Disrupting the Market for Ineffective Medical Devices. , 2022, , 179-191.		11
27	Preventing Medical Device-Borne Outbreaks. , 2022, , 192-202.		0
28	SARS-CoV-2 Laboratory-Developed Tests. JAMA - Journal of the American Medical Association, 2022, 327, 1229.	7.4	5
29	Compulsory Medical Device Registries. , 2022, , 229-243.		0
30	Lifecycle Regulation and Evaluation of Artificial Intelligence and Machine Learning-Based Medical Devices., 2022,, 13-21.		0
31	Volume Introduction. , 2022, , 1-10.		11
32	The Interaction of the Medical Device Regulation and the GDPR. , 2022, , 77-90.		2
33	Regulating Devices that Create Life. , 2022, , 203-214.		1
34	Regulation of Digital Health Technologies in the European Union. , 2022, , 103-114.		1
35	Are Electronic Health Records Medical Devices?., 2022,, 36-46.		1
36	Clouded Judgment. , 2022, , 165-178.		0

#	Article	IF	Citations
37	Professional Self-Regulation in Medicine. , 2022, , 244-255.		11
38	The hospital-at-home presents novel liabilities for physicians, hospitals, caregivers, and patients. Nature Medicine, 2022, 28, 438-441.	30.7	6
39	Ethics-by-design: efficient, fair and inclusive resource allocation using machine learning. Journal of Law and the Biosciences, 2022, 9, lsac012.	1.6	9
40	Stamping Out the Medicaid Coverage Gap: An ACA Imperative. American Journal of Medicine, 2022, , .	1.5	0
41	The CMS Vaccine Mandate at the Supreme Court: A Hippocratic Imperative. American Journal of Medicine, 2022, , .	1.5	0
42	When Is a Change Significant? The Update Problem of Apps in Medical and Behavioral Research. Ethics &	0.9	0
43	What Overturning <i>Roe v Wade</i> May Mean for Assisted Reproductive Technologies in the US. JAMA - Journal of the American Medical Association, 2022, 328, 15.	7.4	14
44	Skating the line between general wellness products and regulated devices: strategies and implications. Journal of Law and the Biosciences, 2022, 9, .	1.6	9
45	The End of <i>Roe v Wade</i> and New Legal Frontiers on the Constitutional Right to Abortion. JAMA - Journal of the American Medical Association, 2022, 328, 325.	7.4	5
46	Artificial Intelligence and Liability in Medicine: Balancing Safety and Innovation. Milbank Quarterly, 2021, 99, 629-647.	4.4	44
47	Legal and Ethical Issues in the Report <i>Heritable Human Genome Editing</i> . Hastings Center Report, 2021, 51, 8-12.	1.0	5
48	Direct-to-consumer medical machine learning and artificial intelligence applications. Nature Machine Intelligence, 2021, 3, 283-287.	16.0	28
49	The Interstate Medical Licensure Compact. JAMA - Journal of the American Medical Association, 2021, 325, 1607.	7.4	20
50	Digital Health Passes in the Age of COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1933.	7.4	38
51	Industry-Sponsored Speaker Programsâ€"End of the Line?. JAMA - Journal of the American Medical Association, 2021, 325, 1835.	7.4	2
52	Legislation to Criminalize Gender-Affirming Medical Care for Transgender Youth. JAMA - Journal of the American Medical Association, 2021, 325, 2251.	7.4	47
53	The American Rescue Plan Act of 2021. JAMA - Journal of the American Medical Association, 2021, 326, 27-28.	7.4	1
54	Beware explanations from Al in health care. Science, 2021, 373, 284-286.	12.6	87

#	Article	IF	Citations
55	The Myth of "Anonymous―Gamete Donation in the Age of Direct-to-Consumer Genetic Testing. , 2021, , 93-106.		3
56	Genetic Paparazzi., 2021,, 113-124.		0
57	In Favor of an Action for Genetic Conversion. , 2021, , 39-50.		1
58	Introduction to Part V., 2021,, 231-232.		0
59	Consuming Genetics As a Life Insurance Consumer. , 2021, , 26-38.		0
60	Noninvasive Prenatal Genome Sequencing. , 2021, , 81-92.		1
61	Governance in the Era of CRISPR and DIY-Bio. , 2021, , 65-76.		0
62	Generational Failures of Law and Ethics. , 2021, , 173-185.		0
63	An Ethical Framework for Genetic Counseling in the Genomic Era. , 2021, , 233-245.		1
64	Precision Medicine and the Resurgence of Race in Genomic Medicine. , 2021, , 186-197.		0
65	Governing Nontraditional Gene Editing., 2021,, 145-156.		1
66	Physician-Mediated Elective Whole Genome Sequencing Tests., 2021,, 246-259.		0
67	Liability Implications of Direct-to-Consumer Genetic Testing. , 2021, , 15-25.		1
68	Programming Our Genomes, Programming Ourselves. , 2021, , 129-144.		0
69	Privacy Best Practices for Direct-to-Consumer Genetic Testing Services. , 2021, , 260-276.		0
70	Regulatory and Medical Aspects of DTC Genetic Testing. , 2021, , 277-292.		1
71	Direct-to-Consumer Genomics and Personal Health Data. , 2021, , 51-64.		0
72	Finding a Regulatory Balance for Genetic Biohacking. , 2021, , 157-168.		0

#	Article	lF	Citations
73	Improving Commercial Genetic Data-Sharing Policy. , 2021, , 107-112.		O
74	Investigative Genetic Genealogy and the Problem of Familial Forensic Identification., 2021,, 211-228.		0
75	Losing Our Minds?. , 2021, , 198-210.		0
76	Mitochondrial disease: Replace or edit?. Science, 2021, 373, 1200-1201.	12.6	9
77	Enforcement of the Physician Payments Sunshine Act. JAMA - Journal of the American Medical Association, 2021, 326, 807.	7.4	4
78	Governing Human Germline Editing Through Patent Law. JAMA - Journal of the American Medical Association, 2021, 326, 1149.	7.4	2
79	The Supreme Court, the Texas Abortion Law (SB8), and the Beginning of the End of <i>Roe v Wade</i> ?. JAMA - Journal of the American Medical Association, 2021, 326, 1473.	7.4	16
80	An Overdue Executive Order: Reinstating the National Bioethics Commission. American Journal of Medicine, 2021, 134, 1199-1200.	1.5	1
81	How Much Can Potential Jurors Tell Us About Liability for Medical Artificial Intelligence?. Journal of Nuclear Medicine, 2021, 62, 15-16.	5.0	20
82	The Affordable Care Act Resurrected. JAMA - Journal of the American Medical Association, 2021, 326, 1797-1798.	7.4	2
83	Beyond Security Patchesâ€"Fundamental Incentive Problems in Health Care Cybersecurity. JAMA Health Forum, 2021, 2, e212969.	2.2	2
84	Psychedelic therapy: a roadmap for wider acceptance and utilization. Nature Medicine, 2021, 27, 1669-1671.	30.7	25
85	Antiviral Therapeutics: Key to Curbing the COVID-19 Pandemic. American Journal of Medicine, 2021, , .	1.5	0
86	What Makes Artificial Intelligence Exceptional in Health Technology Assessment?. Frontiers in Artificial Intelligence, 2021, 4, 736697.	3.4	26
87	A Divisive Ruling on Devices â€" Genus Medical Technologies v. FDA. New England Journal of Medicine, 2021, , .	27.0	0
88	Private Rights and the Public Interest in Drug and Medical Device Litigation. JAMA Internal Medicine, 2020, 180, 299.	5.1	1
89	Gene Editing Sperm and Eggs (not Embryos). Journal of Law, Medicine and Ethics, 2020, 48, 619-621.	0.9	4
90	Humanizing Clinical Care for Patients with Disabilities. , 2020, , 117-128.		2

#	Article	IF	CITATIONS
91	Making "Meaningful Access―Meaningful: Equitable Healthcare for Divisive Times. , 2020, , 147-158.		O
92	The Privacy Problem in Disability Antidiscrimination Law. , 2020, , 159-170.		1
93	Sexual Agency As a Rights-Based Imperative for Persons with Intellectual Disabilities. , 2020, , 171-182.		0
94	Destigmatizing Disability in the Law of Immigration Admissions. , 2020, , 187-199.		0
95	Can We Universally Accommodate Mental Health and Should We? A Systematic Review of the Evidence and Ethical Analysis., 2020,, 227-241.		0
96	Algorithmic Disability Discrimination. , 2020, , 242-254.		4
97	The Pathways Approach to Priority Setting: Considering Quality of Life While Being Fair to Individuals with Disabilities., 2020,, 255-265.		0
98	Measuring Health-State Utility via Cured Patients. , 2020, , 266-280.		2
99	Introduction to Part V., 2020, , 185-186.		0
100	The Normative Bases of Medical Civil Rights. , 2020, , 200-210.		0
101	Introduction to Part VI., 2020, , 223-226.		0
102	Judicial Representation: Speaking for Others from the Bench., 2020,, 211-220.		2
103	The Down Syndrome Information Act and "Mere Difference― Redefining the Scope of Prenatal Testing Conversations?. , 2020, , 64-76.		2
104	Dementia, Disability, and Advance Medical Directives: Defensible Standards for Dementia Care. , 2020, , 77-88.		1
105	Expressing Respect for People with Disabilities in Medical Practice. , 2020, , 93-103.		1
106	Disabled Bodies and Good Organs. , 2020, , 104-116.		0
107	Chronic Pain As a Challenge for Disability Theory and Policy. , 2020, , 129-140.		1
108	Regulatory, safety, and privacy concerns of home monitoring technologies during COVID-19. Nature Medicine, 2020, 26, 1176-1182.	30.7	94

#	Article	IF	CITATIONS
109	Universal Masking in the United States. JAMA - Journal of the American Medical Association, 2020, 324, 837.	7.4	44
110	Heritable Human Genome Editing. JAMA - Journal of the American Medical Association, 2020, 324, 1941.	7.4	6
111	Ethical and Legal Implications of Remote Monitoring of Medical Devices. Milbank Quarterly, 2020, 98, 1257-1289.	4.4	20
112	Disruptive Synergy: Melding of Human Genetics and Clinical Assisted Reproduction. Cell Reports Medicine, 2020, 1, 100093.	6.5	4
113	The Case for Remedial Germline Editing—The Long-term View. JAMA - Journal of the American Medical Association, 2020, 323, 1762.	7.4	0
114	Digital Smartphone Tracking for COVID-19. JAMA - Journal of the American Medical Association, 2020, 323, 2371.	7.4	83
115	Healthcare As Eugenics., 2020,, 20-32.		3
116	The European artificial intelligence strategy: implications and challenges for digital health. The Lancet Digital Health, 2020, 2, e376-e379.	12.3	51
117	Reproduction reimagined. F&S Reports, 2020, 1, 7-8.	0.7	2
118	Disability, Health, and Normal Function., 2020,, 5-19.		1
119	Abortion, the Disabilities of Pregnancy, and the Dignity of Risk. , 2020, , 51-63.		0
120	Preventing Female Genital Mutilation in the United States: The Legal Threat to Effective Action. American Journal of Public Health, 2020, 110, 813-814.	2.7	0
121	What would responsible remedial human germline editing look like?. Nature Biotechnology, 2020, 38, 398-400.	17.5	3
122	Potential Legal Liability for Withdrawing or Withholding Ventilators During COVID-19. JAMA - Journal of the American Medical Association, 2020, 323, 1901.	7.4	88
123	HIPAA in the Era of Data Sharing—Reply. JAMA - Journal of the American Medical Association, 2020, 323, 477.	7.4	1
124	Ethical and Legal Aspects of Ambient Intelligence in Hospitals. JAMA - Journal of the American Medical Association, 2020, 323, 601.	7.4	36
125	The Regulation of Mitochondrial Replacement Techniques Around the World. Annual Review of Genomics and Human Genetics, 2020, 21, 565-586.	6.2	28
126	Therapeutic Germline Editing: Sense and Sensibility. Trends in Genetics, 2020, 36, 315-317.	6.7	4

#	Article	IF	Citations
127	Commentary on â€~Gestation, Equality and Freedom: Ectogenesis as a Political Perspective'. Journal of Medical Ethics, 2020, 46, 87-88.	1.8	4
128	Epistemic Injustice, Disability Stigma, and Public Health Law., 2020,, 33-46.		0
129	The need for a system view to regulate artificial intelligence/machine learning-based software as medical device. Npj Digital Medicine, 2020, 3, 53.	10.9	122
130	Heritable Human Genome Editing: The Public Engagement Imperative. CRISPR Journal, 2020, 3, 434-439.	2.9	17
131	The Case for Remedial Germline Editing—The Long-term View. JAMA Health Forum, 2020, 1, e200241.	2.2	0
132	June Medical Services v Russoâ€"the Future of Abortion Access in the US. JAMA Health Forum, 2020, 1, e201107.	2.2	1
133	Assisted Same-Sex Reproduction: The Promise of Haploid Stem Cells?. Stem Cells and Development, 2020, 29, 1417-1419.	2.1	0
134	Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries. Nature Medicine, 2019, 25, 1198-1204.	30.7	46
135	Big Data, Big Tech, and Protecting Patient Privacy. JAMA - Journal of the American Medical Association, 2019, 322, 1141.	7.4	85
136	The Law and Ethics of Fetal Burial Requirements for Reproductive Health Care. JAMA - Journal of the American Medical Association, 2019, 322, 1347.	7.4	1
137	Ethical and legal issues of ingestible electronic sensors. Nature Electronics, 2019, 2, 329-334.	26.0	36
138	The European Medicines Agency's Approach to Transparency. , 2019, , 210-226.		1
139	Designing development programs for non-traditional antibacterial agents. Nature Communications, 2019, 10, 3416.	12.8	46
140	Nontransparency in Electronic Health Record Systems. , 2019, , 273-285.		0
141	Smashing into Windows. , 2019, , 17-29.		1
142	The Interplay of Privacy and Transparency in Health Care. , 2019, , 30-43.		0
143	Transparency Trade-offs. , 2019, , 44-57.		0
144	Slightly Hazy. , 2019, , 58-68.		0

#	Article	IF	CITATIONS
145	Transparency versus Informed Consent. , 2019, , 75-87.		O
146	Transparency and Financial Conflicts. , 2019, , 88-102.		O
147	Making Religion Transparent. , 2019, , 103-114.		0
148	Transparency on Prescription Drug Research Expenditures. , 2019, , 121-131.		0
149	Is Pharmaceutical Price Transparency an Effective Means to Reduce High Prices and Wide Variations?., 2019, , 132-152.		1
150	Solving Surprise Medical Bills., 2019, , 165-178.		0
151	Increasing the Transparency of FDA Review to Enhance the Innovation Process. , 2019, , 185-195.		O
152	Transparency and Clinical Trial Data Sharing. , 2019, , 196-209.		0
153	Introduction to Part V., 2019, , 229-232.		O
154	The Role of Transparency in Promoting Healthy Behaviors. , 2019, , 233-243.		0
155	The Role of Transparency in Patient Safety Improvement. , 2019, , 244-259.		O
156	Personal Health Records as a Tool for Transparency in Health Care. , 2019, , 260-272.		0
157	Transparency Challenges in Reproductive Health Care. , 2019, , 286-296.		O
158	Introduction to Part VI., 2019, , 299-300.		0
159	ERISA as a Barrier for State Health Care Transparency Efforts. , 2019, , 301-313.		O
160	Transparency and Data Sharing in Clinical Research and Big Pharma. , 2019, , 314-328.		0
161	Promoting IRB Transparency. , 2019, , 329-342.		0
162	Using Disclosure to Regulate PBMs. , 2019, , 343-356.		1

#	Article	IF	Citations
163	Price Transparency. , 2019, , 153-164.		1
164	How does emerging patent case law in the US and Europe affect precision medicine?. Nature Biotechnology, 2019, 37, 1118-1125.	17. 5	11
165	Potential Liability for Physicians Using Artificial Intelligence. JAMA - Journal of the American Medical Association, 2019, 322, 1765.	7.4	236
166	In support of mitochondrial replacement therapy. Nature Medicine, 2019, 25, 870-871.	30.7	10
167	A Troubling Court Decision for Reproductive Rights. JAMA - Journal of the American Medical Association, 2019, 322, 23.	7.4	1
168	How bans on germline editing deprive patients with mitochondrial disease. Nature Biotechnology, 2019, 37, 589-592.	17.5	5
169	When science and politics collide: Enhancing the FDA. Science, 2019, 364, 628-631.	12.6	10
170	Stem Cell-Derived Human Gametes: The Public Engagement Imperative. Trends in Molecular Medicine, 2019, 25, 165-167.	6.7	7
171	Algorithms on regulatory lockdown in medicine. Science, 2019, 366, 1202-1204.	12.6	64
172	Medical Crowdfunding for Unproven Medical Treatments: Should Gofundme Become a Gatekeeper?. Hastings Center Report, 2019, 49, 32-38.	1.0	12
173	Privacy in the age of medical big data. Nature Medicine, 2019, 25, 37-43.	30.7	572
174	A Framework for Ethical Payment to Research Participants. New England Journal of Medicine, 2018, 378, 766-771.	27.0	111
175	Truth in Advertising: Disclosure of Participant Payment in Research Recruitment Materials. Therapeutic Innovation and Regulatory Science, 2018, 52, 268-274.	1.6	4
176	Preventing Mitochondrial Disease. Obstetrics and Gynecology, 2018, 131, 553-556.	2.4	4
177	On Scarcity and the Value of Clinical Trials. American Journal of Bioethics, 2018, 18, 71-73.	0.9	1
178	Preventing Mitochondrial Diseases: Embryo-Sparing Donor-Independent Options. Trends in Molecular Medicine, 2018, 24, 449-457.	6.7	18
179	Future-proofing global health: Governance of priorities. Global Public Health, 2018, 13, 519-527.	2.0	50
180	Patient entered Outcomes Research: Stakeholder Perspectives and Ethical and Regulatory Oversight Issues. IRB: Ethics & Human Research, 2018, 40, 7-17.	0.8	15

#	Article	IF	Citations
181	Losing Embryos, Finding Justice: Life, Liberty, and the Pursuit of Personhood. Annals of Internal Medicine, 2018, 169, 800.	3.9	3
182	Machine learning in medicine: Addressing ethical challenges. PLoS Medicine, 2018, 15, e1002689.	8.4	351
183	The Lumbering Crawl Toward Human Germline Editing. Journal of Law, Medicine and Ethics, 2018, 46, 1010-1012.	0.9	0
184	The Ethics of Heritable Genome Editing. JAMA - Journal of the American Medical Association, 2018, 320, 2531.	7.4	5
185	The Ethics of Smart Pills and Self-Acting Devices: Autonomy, Truth-Telling, and Trust at the Dawn of Digital Medicine. American Journal of Bioethics, 2018, 18, 38-47.	0.9	63
186	HIPAA and Protecting Health Information in the 21st Century. JAMA - Journal of the American Medical Association, 2018, 320, 231.	7.4	118
187	Personhood and the Three Branches of Government. New England Journal of Medicine, 2018, 378, 2453-2455.	27.0	5
188	Regulation of Stem Cell Therapy Travel. Current Stem Cell Reports, 2018, 4, 220-227.	1.6	5
189	Building Capacity for a Global Genome Editing Observatory: Conceptual Challenges. Trends in Biotechnology, 2018, 36, 639-641.	9.3	28
190	Building Capacity for a Global Genome Editing Observatory: Institutional Design. Trends in Biotechnology, 2018, 36, 741-743.	9.3	23
191	IRB Oversight of Patient-Centered Outcomes Research: A National Survey of IRB Chairpersons. Journal of Empirical Research on Human Research Ethics, 2018, 13, 421-431.	1.3	6
192	Patient-Centered Outcomes Research: Stakeholder Perspectives and Ethical and Regulatory Oversight Issues. IRB: Ethics & Human Research, 2018, 40, 7-17.	0.8	6
193	Disruptive reproductive technologies. Science Translational Medicine, 2017, 9, .	12.4	30
194	Medical Tourism, Medical Migration, and Global Justice: Implications for Biosecurity in a Globalized World. Medical Law Review, 2017, 25, 200-222.	0.5	6
195	Your Money or Your Patient's Life? Ransomware and Electronic Health Records. Annals of Internal Medicine, 2017, 167, 587.	3.9	10
196	Influence, integrity, and the FDA: An ethical framework. Science, 2017, 357, 876-877.	12.6	1
197	Artificial Wombs and Abortion Rights. Hastings Center Report, 2017, 47, inside back cover.	1.0	12
198	Mitochondrial replacement therapy: born in the USA: theÂuntold story of a conceptual breakthrough. American Journal of Obstetrics and Gynecology, 2017, 217, 561-563.	1.3	6

#	Article	IF	Citations
199	When clinical trials compete: prioritising study recruitment. Journal of Medical Ethics, 2017, 43, 803-809.	1.8	37
200	Brain Death Rejected., 2017,, 293-305.		1
201	Religious Outliers. , 2017, , 173-186.		2
202	A Common Law Duty to Disclose Conscience-Based Limitations on Medical Practice., 2017,, 187-197.		3
203	Religion and Reproductive Technology. , 2017, , 360-371.		2
204	Consensus Statement on Electronic Health Predictive Analytics: A Guiding Framework to Address Challenges. EGEMS (Washington, DC), 2017, 4, 3.	2.0	41
205	Germ-Line Gene Editing and Congressional Reaction in Context: Learning From Almost 50 Years of Congressional Reactions to Biomedical Breakthroughs. Journal of Law and Health, 2017, 30, 20-54.	0.2	1
206	The FDA is prohibited from going germline. Science, 2016, 353, 545-546.	12.6	34
207	Preventing Mitochondrial DNA Diseases. JAMA - Journal of the American Medical Association, 2016, 316, 273.	7.4	10
208	Clinical decision making regarding suicide risk: Effect of patient and clinician age. Death Studies, 2016, 40, 269-274.	2.7	9
209	Going Germline: Mitochondrial Replacement as a Guide to Genome Editing. Cell, 2016, 164, 832-835.	28.9	18
210	Mitchochondrial replacement therapy: the IOM report and its aftermath. Nature Reviews Genetics, 2016, 17, 189-190.	16.3	9
211	Effect of a legal prime on clinician's assessment of suicide risk. Death Studies, 2016, 40, 61-67.	2.7	4
212	This Is Your Brain on Human Rights: Moral Enhancement and Human Rights. Law and Ethics of Human Rights, 2015, 9, 1-41.	0.4	2
213	Medical tourism for services illegal in patients' home country. , 2015, , .		1
214	Inbound medical tourism to Barbados: a qualitative examination of local lawyers' prospective legal and regulatory concerns. BMC Health Services Research, 2015, 15, 291.	2.2	9
215	Hospital-Based Active Shooter Incidents. JAMA - Journal of the American Medical Association, 2015, 313, 1209.	7.4	10
216	Transatlantic lessons in regulation of mitochondrial replacement therapy. Science, 2015, 348, 178-180.	12.6	43

#	Article	IF	Citations
217	Reconsideration of the Lifetime Ban on Blood Donation by Men Who Have Sex With Men. JAMA - Journal of the American Medical Association, 2014, 312, 337.	7.4	13
218	Physicians, Medical Ethics, and Execution by Lethal Injection. JAMA - Journal of the American Medical Association, 2014, 311, 2375.	7.4	9
219	Clinical Trials and the Right to Remain Silent. JAMA Internal Medicine, 2014, 174, 1505.	5.1	1
220	A Fuller Picture of Organ Markets. American Journal of Bioethics, 2014, 14, 19-21.	0.9	33
221	The Legal And Ethical Concerns That Arise From Using Complex Predictive Analytics In Health Care. Health Affairs, 2014, 33, 1139-1147.	5.2	189
222	Of Modest Proposals and Non-Identity: A Comment on the Right to Know Your Genetic Parents. American Journal of Bioethics, 2013, 13, 45-47.	0.9	1
223	Plan B: access to emergency contraception in the legal and political cross hairs. Contraception, 2013, 88, 477-480.	1.5	1
224	Making Residency Work Hour Rules Work. Journal of Law, Medicine and Ethics, 2013, 41, 310-314.	0.9	6
225	Made-to-Order Embryos for Sale — A Brave New World?. New England Journal of Medicine, 2013, 368, 2517-2519.	27.0	11
226	Transplant Tourism: The Ethics and Regulation of International Markets for Organs. Journal of Law, Medicine and Ethics, 2013, 41, 269-285.	0.9	53
227	The Constitutionality of the ACA's Medicaid-Expansion Mandate. New England Journal of Medicine, 2012, 366, 103-104.	27.0	2
228	Selling Bone Marrow â€" <i>Flynn v. Holder</i> . New England Journal of Medicine, 2012, 366, 296-297.	27.0	5
229	S.H. and Others v. Austria and circumvention tourism. Reproductive BioMedicine Online, 2012, 25, 660-662.	2.4	4
230	HOW TO REGULATE MEDICAL TOURISM (AND WHY IT MATTERS FOR BIOETHICS). Developing World Bioethics, 2012, 12, 9-20.	0.9	30
231	Sherley v Sebelius and the Future of Stem Cell Research. JAMA - Journal of the American Medical Association, 2012, 308, 2087.	7.4	2
232	Can the Government Ban Organ Sale? Recent Court Challenges and the Future of US Law on Selling Human Organs and Other Tissue. American Journal of Transplantation, 2012, 12, 1983-1987.	4.7	11
233	Fetal Pain, Abortion, Viability, and the Constitution. Journal of Law, Medicine and Ethics, 2011, 39, 235-242.	0.9	11
234	Prohibiting Anonymous Sperm Donation and the Child Welfare Error. Hastings Center Report, 2011, 41, 13-14.	1.0	2

#	Article	IF	Citations
235	Human Embryonic Stem-Cell Research under Siege â€" Battle Won but Not the War. New England Journal of Medicine, 2011, 364, e48.	27.0	17
236	Medical Tourism: The View from Ten Thousand Feet. Hastings Center Report, 2010, 40, 11-12.	1.0	22
237	Not Your Father's Religious Exemptions: The Contraceptive- Coverage Litigation and the Rights of Others., 0,, 60-74.		0
238	Unpacking the Relationship Between Conscience and Access., 0,, 242-258.		0
239	Accommodating Miracles: Medical Futility and Religious Free Exercise. , 0, , 306-318.		0
240	RELIGION AND REPRODUCTIVE HEALTH CARE: INTRODUCTION., 0,, 345-347.		0
241	Contracting Religion. , 0, , 113-124.		0
242	Introduction: Law, Religion, and Health in the United States. , 0, , 1-18.		0
243	LAW, RELIGION, AND HEALTH CARE INSTITUTIONS: INTRODUCTION. , 0, , 87-89.		0
244	Mission Integrity Matters: Balancing Catholic Health Care Values and Public Mandates., 0,, 125-138.		0
245	Bosses in the Bedroom: Religious Employers and the Future of Employer- Sponsored Health Care. , 0, , 154-168.		0
246	PROFESSIONAL RESPONSIBILITIES, RELIGION, AND HEALTH CARE: INTRODUCTION. , 0, , 169-172.		0
247	Religious Convictions About Homosexuality and the Training of Counseling Professionals: How Should We Treat Religious- Based Opposition to Counseling About Same- Sex Relationships?., 0,, 263-275.		0
248	Religion and the Unborn Under the First Amendment. , 0, , 372-382.		0
249	Race, Religion, and Masculinity: The HIV Double Bind. , 0, , 387-398.		O
250	Religious Liberty, Health Care, and the Culture Wars. , 0, , 21-33.		0
251	Religious Exemptions to the Individual Mandate: Health Care Sharing Ministries and the Affordable Care Act., 0,, 143-153.		0
252	How Much May Religious Accommodations Burden Others?., 0,, 215-229.		3

#	Article	IF	CITATIONS
253	A Corporation's Exercise of Religion: A Practitioner's Experience. , 0, , 90-102.		O
254	"A Patchwork Array of Theocratic Fiefdoms?―RFRA Claims Against the ACA's Contraception Mandate as Examples of the New Feudalism. , 0, , 230-241.		0
255	The HHS Mandate Litigation and Religious Health Care Providers. , 0, , 47-59.		O
256	Recent Applications of the Supreme Court's Hands- Off Approach to Religious Doctrine: From Hosanna- Tabor and Holt to Hobby Lobby and Zubik., 0,, 75-86.		0
257	A CASE STUDY – RELIGIOUS BELIEFS AND THE HEALTH OF THE LGBT COMMUNITY: INTRODUCTION. , 0, , 259-262.		O
258	When Religion Pollutes: How Should Law Respond When Religious Practice Threatens Public Health?. , 0, , 411-422.		0
259	From Smith to Hobby Lobby: The Transformation of the Religious Freedom Restoration Act., 0,, 34-46.		O
260	The Natural Person as the Limiting Principle for Conscience: Can a Corporation Have a Conscience If It Doesn't Have an Intellect and Will?. , 0 , , $103-112$.		0
261	Conscientious Objection, Complicity, and Accommodation. , 0, , 203-214.		O
262	Reclaiming Biopolitics: Religion and Psychiatry in the Sexual Orientation Change Therapy Cases and the Establishment Clause Defense., 0,, 276-288.		1
263	Putting the Insanity Defense on Trial: Understanding Criminality in the Context of Religion and Mental Illness., 0,, 319-331.		O
264	Religion as a Controlling Interference in Medical Decision Making by Minors., 0,, 332-344.		0
265	Regulating Reasons: Governmental Regulation of Private Deliberation in Reproductive Decision Making., 0,, 348-359.		O
266	RELIGION, LAW, AND PUBLIC HEALTH: INTRODUCTION. , 0, , 383-386.		0
267	The Intersection of Law, Religion, and Infectious Disease in the Handling and Disposition of Human Remains., 0,, 399-410.		O
268	Big Data and Individual Autonomy in a Crowd. , 0, , 19-29.		1
269	Big Data's Epistemology and Its Implications for Precision Medicine and Privacy. , 0, , 30-41.		2
270	Correlation versus Causation in Health-Related Big Data Analysis., 0,, 42-55.		3

#	Article	IF	CITATIONS
271	Big Data and Regulatory Arbitrage in Healthcare. , 0, , 56-68.		2
272	The Future of Pharmacovigilance. , 0, , 73-84.		1
273	Big Data's New Discrimination Threats. , 0, , 85-97.		4
274	Who's Left Out of Big Data?. , 0, , 98-111.		3
275	Potential Roadblocks in Healthcare Big Data Collection. , 0, , 112-124.		O
276	Avoiding Overregulation in the Medical Internet of Things. , 0, , 129-141.		4
277	Data Policy for Internet of Things Healthcare Devices. , 0, , 142-156.		O
278	Thought-Leader Perspectives on Risks in Precision Medicine Research. , 0, , 161-174.		2
279	From Individual to Group Privacy in Biomedical Big Data. , 0, , 175-192.		O
280	Big Data and Informed Consent. , 0, , 193-204.		0
281	Is There a Duty to Share Healthcare Data?. , 0, , 209-222.		13
282	Societal Lapses in Protecting Individual Privacy, the Common Rule, and Big Data Health Research. , 0, , 223-236.		0
283	The Common Rule and Research with Data, Big and Small. , 0, , 237-250.		1
284	Big Data, HIPAA, and the Common Rule. , 0, , 251-264.		2
285	Data Sharing that Enables Postapproval Drug and Device Research and Protects Patient Privacy. , 0, , 269-282.		O
286	Big Data and Human Medical Judgment. , 0, , 283-294.		1
287	Medical Malpractice and Black-Box Medicine. , 0, , 295-306.		18
288	Big Data and Intellectual Property Rights in the Health and Life Sciences. , 0, , 311-323.		9

#	Article	IF	CITATIONS
289	The Pathologies of Data-Generating Patents. , 0, , 324-336.		1
290	Ethical and Legal Challenges of Artificial Intelligence-Driven Health Care. SSRN Electronic Journal, 0, , .	0.4	12